Is Elicio Therapeutics Inc. (ELTX) overvalued? · $132.3M cap
Elicio Therapeutics Inc. (ELTX) is a biotechnology company listed on US.
This page asks whether Elicio Therapeutics Inc. (ELTX) looks expensive on cached numbers — not a short thesis.
Latest reported ELTX revenue for 2023-03-31 was $0. Net income was -$8.0M. Revenue was down 100.0% from 2022-12-31 to 2023-03-31. ELTX currently screens at market cap $132.3M.
ELTX currently screens at market cap $132.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ELTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ELTX stock page for the full model, not this heading.
Not investment advice.